Skip to main content

Table 2 Incidences of primary effectiveness outcomes in patients receiving TKA

From: Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study

  Fondaparinux Enoxaparin UFH Others Medication (-) Total
n = 360 (%) n = 223 (%) n = 72 (%) n = 45 (%) n = 594 (%) n = 1,294 (%)
All venous thromboembolism 61 (16.9) 59 (26.5) 24 (33.3) 12 (26.7) 158 (26.6) 314 (24.3)
  Any DVT (up to POD10 ) 60 (16.7) 59 (26.5) 24 (33.3) 12 (26.7) 158 (26.6) 314 (24.3)
  Symptomatic DVT 2 (0.6) 3 (1.3) 0 1 (2.2) 6 (1.0) 12 (0.9)
   Distal 1 (0.3) 2 (0.9) 0 1 (2.2) 4 (0.7) 8 (0.6)
   Proximal 1 (0.3) 1 (0.4) 0 0 2 (0.3) 4 (0.3)
  Non-symptomatic DVT 59 (16.4) 56 (25.1) 24 (33.3) 11 (24.4) 152 (25.6) 302 (23.3)
   Distal 51 (14.2) 52 (23.3) 21 (29.2) 11 (24.4) 133 (22.4) 268 (20.7)
   Proximal 8 (2.2) 4 (1.8) 3 (4.2) 0 19 (3.2) 34 (2.6)
  PE (up to POD28) 1 (0.3) 0 0 0 1 (0.2) 2 (0.2)
  1. CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; POD, post-operative day; TKA, total knee arthroplasty; UFH, unfractionated heparin.